Meredith Manning serves as the Chief Commercial Officer at Soleno Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. With a robust background in the pharmaceutical industry, Manning brings a wealth of experience and strategic insight to her role. She has spent over two decades in various leadership positions within the sector, driving commercial success and overseeing the launch of multiple high-profile products. Prior to joining Soleno Therapeutics, Manning held significant roles at several major pharmaceutical companies. Notably, she served as the Vice President of Global Commercial Strategy at Genentech, where she was instrumental in the successful market entry and growth of several blockbuster drugs. Her strategic vision and ability to navigate complex market dynamics have been pivotal in her career. At Soleno Therapeutics, Manning is responsible for steering the company’s commercial strategy, particularly in preparing for the potential launch of their lead product candidate, aimed at treating Prader-Willi syndrome. Manning's achievements are not only limited to her commercial acumen but also extend to her contributions to industry thought leadership. She has been a frequent speaker at industry conferences, sharing insights on market access, patient engagement, and the evolving landscape of rare disease treatments. Her role at Soleno is crucial as the company advances towards bringing innovative therapies to patients, and her leadership is expected to be a key driver in realizing the company's mission of transforming the lives of those affected by rare diseases.